RE:Nothing unusual ...I agree. The accumulation game is the way to go as you've mentioned countless times. The operational trend is our friend but the market is more and more short term oriented.
Analysts have downgraded the stock but there are big buyers coming in above 5$
* Raymond James’ David Novak to $7.50 from $8.50 with an “outperform” rating.
“Considering the ongoing valuation deflation plaguing the broader healthcare/biotech sector, as evidenced by the XBI which is now tracking down 30.7 per cent on a TTM [trailing 12-month] basis vs. the S&P 500 tracking up 15.6 per cent over the same time frame, we continue to view Knight as one of the best defensive names to own in the Canadian healthcare sector,” he said. “Furthermore, Knight’s current free cash flow profile, well capitalized balance sheet, and future growth profile, positions the company well in a raising inflationary environment, where many healthcare equities continue to be impacted by the devaluation of future cash flows.”